Articles
Ideas shaping biotechnology growth—commercial leadership, launch strategy, and rare disease insights from PharmaKonsult.
Rare Disease Market Size: Why Prevalence Is Not the Commercial Opportunity
Prevalence describes how many people may have a rare disease. Commercial opportunity depends on diagnosis, reach, access and treatment initiation.
Read articleBuild or Outsource? Designing the First Commercial Organization for an Emerging Biotech
Decide what to build internally and what to outsource when designing an emerging biotechnology company's first commercial organization.
Read articleHow Medical Affairs and Commercial Teams Should Prepare Together for Launch
Physicians experience one company. Medical Affairs and Commercial must align around the same market reality, evidence needs and launch governance.
Read articlePreparing a Biotechnology Commercial Strategy for the Board
Board-ready commercial strategy clarifies assumptions, capabilities, investment, risks and decision points—not a slide deck of tactics.
Read articleHow Commercial Strategy Influences Biotechnology Valuation
Investors increasingly ask whether a therapy can succeed commercially. Commercial readiness has become part of enterprise value—not only a post-approval activity.
Read articleMarket Opportunity Assessment for Emerging Biotech
A credible biotech market opportunity assessment challenges diagnosed population, reachability, adoption drivers and access—not epidemiology alone.
Read articleHow to Right-Size a Rare Disease Commercial Organization
More people do not automatically produce a better rare disease launch. Organization design should follow specialist concentration, access burden and patient-support requirements.
Read articlePatient Journey Mapping for Rare Disease Commercialization
Prevalence alone does not define opportunity. Mapping how patients enter care, where diagnosis is delayed and where access breaks down creates a realistic commercial model.
Read article